David Friedland
Overview
Explore the profile of David Friedland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Osafo N, Bock J, Blumin J, Adams J, Friedland D, Luo J
Laryngoscope
. 2024 Oct;
135(4):1335-1342.
PMID: 39440422
Objectives: To assess the correlation of social determinants of health (SDOH) with the general care patterns related to gastroesophageal reflux disease and laryngopharyngeal reflux. Determine correlation of SDOH on utilization...
2.
El-Khoury R, Cabrero C, Movilla S, Kaur H, Friedland D, Dominguez A, et al.
Nucleic Acids Res
. 2024 Jun;
52(13):7414-7428.
PMID: 38874502
Recent findings in cell biology have rekindled interest in Z-DNA, the left-handed helical form of DNA. We report here that two minimally modified nucleosides, 2'F-araC and 2'F-riboG, induce the formation...
3.
Iwanowski P, Bhatia A, Gupta M, Patel A, Chavan R, Yeole R, et al.
Antimicrob Agents Chemother
. 2019 Oct;
63(12).
PMID: 31591119
Nafithromycin (WCK 4873), a novel lactone-ketolide, was administered to healthy adult subjects in 2 randomized, double-blind, placebo-controlled, Phase 1 studies. In the first-in-human study, single-ascending oral doses of nafithromycin (100...
4.
Britt C, Ward B, Owusu Y, Friedland D, Russell J, Weinreich H
JAMA Otolaryngol Head Neck Surg
. 2018 Sep;
144(10):883-886.
PMID: 30178063
Importance: Benign paroxysmal positional vertigo (BPPV) is an otologic pathologic condition defined as a sensation of spinning triggered by changes in head position relative to gravity and caused by an...
5.
Achkar T, Arjunan A, Wang H, Saul M, Davar D, Appleman L, et al.
PLoS One
. 2017 Dec;
12(12):e0190084.
PMID: 29261796
Background: High-dose interleukin-2 (HD IL-2) is used in the treatment of metastatic renal cell carcinoma (mRCC) and has an overall response rate (ORR) of 12-20% and a complete response rate...
6.
Knirsch C, Alemayehu D, Botgros R, Comic-Savic S, Friedland D, Holland T, et al.
Clin Infect Dis
. 2016 Aug;
63 Suppl 2:S29-36.
PMID: 27481950
Background: The etiology of hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is often multidrug-resistant infections. The evaluation of new antibacterial drugs for efficacy in this population is important, as many antibacterial...
7.
Hong D, Gordon M, Samlowski W, Kurzrock R, Tannir N, Friedland D, et al.
Clin Genitourin Cancer
. 2013 Dec;
12(3):167-177.e2.
PMID: 24365125
Background: Trebananib, an investigational peptibody, binds to angiopoietin 1 and 2, thereby blocking their interaction with Tie2. Patients And Methods: This open-label phase I study examined trebananib 3 mg/kg or...
8.
Wilcox M, Corey G, Talbot G, Thye D, Friedland D, Baculik T
J Antimicrob Chemother
. 2010 Dec;
65 Suppl 4:iv53-iv65.
PMID: 21115455
Objectives: New therapies for complicated skin and skin structure infections (cSSSIs) are needed because of significant morbidity and increasing antimicrobial resistance. Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of...
9.
Corey G, Wilcox M, Talbot G, Thye D, Friedland D, Baculik T
J Antimicrob Chemother
. 2010 Dec;
65 Suppl 4:iv41-51.
PMID: 21115454
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a common cause of complicated skin and skin structure infections (cSSSIs). Increasing antibiotic resistance and significant morbidity in cSSSIs have led to...
10.
Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, et al.
Clin Cancer Res
. 2010 Nov;
16(23):5900-7.
PMID: 21045083
Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in previously treated,...